Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Operating Leases (2020 - 2025)

Historic Operating Leases for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to $8.7 million.

  • BridgeBio Pharma's Operating Leases rose 4951.14% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 4951.14%. This contributed to the annual value of $4.7 million for FY2024, which is 4771.18% down from last year.
  • Latest data reveals that BridgeBio Pharma reported Operating Leases of $8.7 million as of Q3 2025, which was up 4951.14% from $4.0 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Operating Leases ranged from a high of $18.7 million in Q3 2021 and a low of $4.0 million during Q2 2025
  • For the 5-year period, BridgeBio Pharma's Operating Leases averaged around $11.0 million, with its median value being $10.9 million (2023).
  • As far as peak fluctuations go, BridgeBio Pharma's Operating Leases soared by 12684.56% in 2021, and later crashed by 4771.18% in 2024.
  • BridgeBio Pharma's Operating Leases (Quarter) stood at $17.4 million in 2021, then decreased by 29.57% to $12.3 million in 2022, then decreased by 26.83% to $9.0 million in 2023, then crashed by 47.71% to $4.7 million in 2024, then surged by 85.71% to $8.7 million in 2025.
  • Its Operating Leases was $8.7 million in Q3 2025, compared to $4.0 million in Q2 2025 and $4.9 million in Q1 2025.